Table 1

Clinical characteristics of study groups

CharacteristicTotal cohortSurvey onlyAccelerometer subsetp Value
Total HCM participants19812672
Males, n (%)125 (63.1%)72 (57.1%)53 (73.6%)0.02*
Age (years), mean±SD48.8±15.348.5±15.849.2±15.00.78
ICD in situ, n (%)78/198 (39.4%)54/126 (42.9%)24/72 (33.3%)0.19
On β-blockers, n (%)97/194 (50.0%)59/123 (48.0%)38/71 (53.2%)0.46
Comorbidities, n (%)111/182 (61.0%)67/116 (57.8%)44/67 (65.7%)0.32
NYHA (>1), n (%)47/196 (24.0%)29/125 (23.2%)18/71 (25.4%)0.73
Maximum LVH, mean±SD22.5±6.423.2±0.621.2±0.70.04*
Documented NSVT, n (%)47/192 (24.5%)34/121 (28.1%)13/71 (18.3%)0.13
History of syncope, n (%)40/177 (22.6)30/115 (26.1%)10/62 (16.2%)0.13
History of LVOTO, n (%)65/198 (32.8%)38/126 (30.2%)27/72 (37.5%)0.29
Maximum gradient (mm Hg), mean±SD39.8±3.736.3±4.446.2±6.80.21
Atrial fibrillation, n (%)42/198 (21.2%)31/126 (24.6%)11/72 (15.3%)0.12
Surgical intervention, n (%)17/189 (9%)9/121 (7.4%)8/68 (11.8%)0.32
Family history of SCD, n (%)38/193 (19.7%)27/122 (22.1%)11/71 (15.5%)0.26
BMI (kg/m2), mean±SD27.6±5.227.5±5.427.7±5.00.76
 Underweight (BMI<18.5)2/194 (1.0%)2/123 (1.6%)0/71 (0.0%)NA
 Normal (BMI 18.5–25)62 (32.0%)39 (31.7%)23 (32.4%)0.92
 Overweight (BMI 25–30)79 (40.7%)50 (40.7%)29 (40.8%)0.98
 Obese (BMI>30)51 (26.3%)32 (26.0%)19 (26.8%)0.91
SEIFA (>8), n (%)109/198 (55.1%)70/126 (55.6%)39/72 (54.2%)0.85
Tertiary educated, n (%)65/188 (34.6%)42/124 (33.9%)23/64 (35.9%)0.78
  • *p<0.05.

  • BMI, body mass index; ICD, implantable cardioverter defibrillator; HCM, hypertrophic cardiomyopathy; LVOTO, left ventricular outflow tract obstruction; LVH, left ventricular wall hypertrophy; NA, not applicable; NSVT, non-sustained ventricular tachycardia; NYHA, New York Heart Association functional classification; SCD, sudden cardiac death; SEIFA, Socio-Economic Indexes for Areas (ranked 1–10, higher score indicates higher socioeconomic status).